ABCL stock forecast 2025 data models indicate possible 20% year-over-year revenue growth if early-stage candidates move into Phase 2 trials. Biotech sector liquidity cycles suggest that sustained investor focus could drive valuation multiples above 8× EV/revenue. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock . Cerus has been struggling to achieve profitability for a long time, which has weighed heavily on its share price. The ABCL stock forecast 2025 suggests potential upside supported by AbCellera’s growing therapeutic antibody pipeline. Analysts tracking Nasdaq biotech indices project earnings per share to trend positive if Q3 2024 clinical trial milestones are achieved. Given rising institutional interest, volatility could remain high in correlation with sector performance.